1. The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: study design, aminoglycosides dosing and technique of nebulisation
- Author
-
Marc Leone, Antoine Monsel, Pierre-François Laterre, Jean-Jacques Rouby, Olivier Mimoz, Jérôme Pugin, CHU Pitié-Salpêtrière [APHP], Immunologie - Immunopathologie - Immunothérapie (I3), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service Anesthésie et Réanimation [Hôpital Nord - APHM], Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Service d'anesthésie réanimation [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Intensive Care Unit, St Luc University Hospital, Intensive Care Medicine Unit, University Hospital of Geneva, UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Pharmacologie des anti-infectieux (PHAR), Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
medicine.medical_specialty ,Epithelial lining fluid ,Critical Care and Intensive Care Medicine ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,medicine ,Tobramycin ,Ventilator-associated pneumonia ,Humans ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,030212 general & internal medicine ,Dosing ,Intensive care medicine ,Amikacin ,ComputingMilieux_MISCELLANEOUS ,Multidrug-resistant Gam-negative bacteria ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,ddc:617 ,business.industry ,Nebulised antibiotics ,General Medicine ,medicine.disease ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,3. Good health ,Anti-Bacterial Agents ,Anesthesiology and Pain Medicine ,Aminoglycosides ,030228 respiratory system ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Gentamicins ,business ,medicine.drug - Abstract
Animal studies demonstrate that nebulised aminoglycosides and colimycin (polymyxin E) deliver higher antibiotic concentrations and greater bactericidal activity in the lung parenchyma infected by both sensitive and multidrug-resistant (MDR) Gramnegative bacteria (GNB) [1]. However, superiority of nebulised over intravenous (IV) aminoglycosides and colimycin in patients with ventilator-associated pneumonia (VAP) remains to be demonstrated. Clinical studies are sparse, heterogeneous in terms of aims and methods, and have enrolled a limited number of patients. As a consequence, recommendations from American and European academic societies for using nebulised antibiotics are limited, based on a weak level-of-evidence and sometimes divergent.[...]
- Published
- 2020